The net benefit of SUVmax and SUVratio was greater for patients within threshold probabilities of 20–95% than PI-RADS, with the outcome as PCa (Fig. 5), suggesting that the clinical utility of 68Ga-PSMA-617 PET/CT was superior to that of mpMRI on most occasions. The gene discussed is FOLH1; the disease is posterior cortical atrophy.